Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FP-02.2 in HBeAg-negative Hepatitis B
NCT02496897Phase 1Completed
- Sponsor
- Altimmune, Inc.
- Start
- Jul 2015
- Primary completion
- Oct 2017
- Modality
- Therapeutic Vaccines
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of HepTcell in Chronic Hepatitis B (CHB) (6 arms), sponsored by Altimmune, Inc. Primary endpoints: Treatment Emergent Adverse Events at Day 85 and Local Injection Site Reactions at Day 64. Started Jul 2015; status: completed.
02
Drugs
HepTcell
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02496897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02496897.